Site Map

Stock Exchange Announcements

Latest Company Information

News

Press Releases 2010 » Avexa Securities Trading Policy | Avexa Dec Roadshow.pdf | Allan Tan appointment to Avexa Board | Avexa secures FDA meeting on ATC | Chairman's presentation to AGM | Avexa licenses Antibacterial program | Company announcement- Allied Medical | Resignation of Crowley | Notice of Annual General Meeting - 18 November 2010 | Proxy form AGM 2010 | Results of 28 Sep 2010 General Meeting | Avexa responds to Calzada Limited | Avexa's letter to Calzada dated 12 August 2010 | Avexa Engages BioAdvisory Group | Proxy Form AUG 2010 | Preliminary Final Report 2010 | Audited Accounts 2010 | Notice Of Meeting AUG | Avexa receives request from Calzada for General Meeting | Avexa appoints new Non-Executive Director | Quarterly News Report to Shareholders for July 2010. | Avexa licenses one of its HIV integrase programs to Chinese partner | Avexa announces new appointments | Avexa Announces Resignation of Director Mr David Bottomley | Avexa appoints new Chairman and Board members | Board Letter to Shareholders | Correction of typographical error in Notice of Meeting | General Meeting Proxy Form | Notice of General Meeting | Avexa appoints Uri Ratner to Board of Directors | Avexa announces resignation of Director Mr Joe Baini | Letter to shareholders | Avexa receives request for general meeting | Avexa closes apricitabine program | March 2010 Quarterly Cash Flow Statement | Avexa announces detailed ATC Phase III results at 24 weeks | Avexa exits CSIRO's AGPP arrangement | Expiry of HIV Integrase Option Period with Tibotec | Avexa reports positive phase IIb 144 week data for HIV drug apricitabine | Avexa announces ATC phase III top line results
Press Releases 2009 » Avexa Closes Share Purchase Plan | Avexa Option Agreement with Tibotec extended | Share Purchase Plan Booklet | Share Purchase Plan Terms and Conditions | Share Placement and Share Purchase Plan | Results of AGM 2009 | Avexa announces resignation of director | Avexa to extend option agreement for HIV program | Appendix 4C September 2009 | Avexa closes ATC's phase III trial to evaluate data | ASX Release/Preliminary Final Report June 2009 | CSIRO invests A$2M in Avexa's HCV program | Avexa announces changes to its board of directors | Positive outcome reached at 16 weeks for Avexa's ATC phase III trial | Update to 2009 capital raising effort | Avexa signs option agreement with Tibotec | Rights Issue completed - $17m raised | Appointment of Mr Joe Baini as Non-Executive Director | Investor Forums April 2009 | Rights Issue Contact Numbers | Avexa Offer Document 2009 | Avexa awarded federal funding to further antiviral discovery with TargetDrug | Shareholder letter | Avexa announces rights issue | Avexa reaches first critical evaluation point for ATC's phase III trial | Stephen Kerr appointed Company Secretary | Avexa reports positive 96 week data for HIV drug apricitabine | Avexa Appoints Stephen Kerr as CFO and Company Secretary | Avexa's Proposed Merger with Progen Terminated | PGL: Withdraws from Avexa Merger Announces $40m Buyback | Investor Forum Presentation | Letter to Progen Shareholders | Financial report for half-year ended 31 December 2008 | Avexa announces half yearly results | Appendix 4D | Avexa and Progen Merger Shareholder Forum Presentation | Avexa despatches Scheme Booklet | Response to inaccurate statement | PGL: Progen-Avexa Merger Notice of Meeting | CYT and other PGL shareholders maintain call for meeting | Progen and Avexa Shareholder Forums | PGL: Merger Notice of Meeting and Independent Expert Report | Avexa Releases Independent Expert Report | PGL: Progen Reaction to Requisition for General Meeting | PGL: Response to Requisitioned General Meeting | CYT: Request for General Meeting of Progen Pharmaceuticals | PGL: Progen and Avexa Merger Update | CFO Resignation | Appendix 4C | PGL: Shareholder Support for Progen Board | Avexa and Progen Merger Investor Forum Presentation

Corporate

Investor Relations

AGM

Presentations

FAQs

Contact Us

Resources